Should I buy or sell PROCEPT BioRobotics stock right now?
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PROCEPT BioRobotics in the last year. There are currentl...
What is PROCEPT BioRobotics' stock price forecast for 2022?
5 brokers have issued twelve-month price objectives for PROCEPT BioRobotics' shares. Their PRCT stock forecasts range from $30.00 to $50.00. On ave...
How has PROCEPT BioRobotics' stock performed in 2022?
PROCEPT BioRobotics' stock was trading at $25.01 at the start of the year. Since then, PRCT stock has increased by 63.5% and is now trading at $40....
When is PROCEPT BioRobotics' next earnings date?
PROCEPT BioRobotics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for...
How were PROCEPT BioRobotics' earnings last quarter?
PROCEPT BioRobotics Co. (NASDAQ:PRCT) released its quarterly earnings results on Thursday, May, 5th. The company reported ($0.39) earnings per shar...
What guidance has PROCEPT BioRobotics issued on next quarter's earnings?
PROCEPT BioRobotics updated its FY 2022 earnings guidance on Monday, May, 30th. The company provided earnings per share (EPS) guidance of for the p...
Who are PROCEPT BioRobotics' key executives?
PROCEPT BioRobotics' management team includes the following people: Dr. Reza Zadno Ph.D. , Pres, CEO & Director (Age 67, Pay $759.5k) Mr. Kevin...
Who are some of PROCEPT BioRobotics' key competitors?
Some companies that are related to PROCEPT BioRobotics include ShockWave Medical (SWAV) , Globus Medical (GMED) , Inspire Medical Systems (INSP)...
When did PROCEPT BioRobotics IPO?
(PRCT) raised $126 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 5,500,000 shares at a price of...
About Procept BioRobotics
Headlines
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. It focused on advancing patient care by developing transformative solutions in urology.
About PRCT
Is PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Worth US$28.4 Based On Its Intrinsic Value?
Analyst Forecast
PROCEPT BioRobotics is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology.
News
According to 5 analysts, the average rating for PRCT stock is "Strong Buy." The 12-month stock price forecast is 43.00, which is an increase of 115.32% from the latest price.
Share your Analysis on PRCT
The U.S. IPO market was red-hot in 2021. The total number of traditional U.S. IPOs hit its highest level since the dot-com boom in the late 1990s, while total IPO deal value reached record levels last y...
Company Profile
Join our contributor community and share your insights with millions of readers across the globe. Submit an article now
PROCEPT BioRobotics (PRCT)
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Zacks' 7 Best Strong Buys for March, 2022
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
5 Top Value Stocks with Strong Growth
We have a proven record of recommending stocks with major upside potential. A recent pick, Fiverr, spiked +84.6% in just 30 days. Our latest report reveals 7 stocks predicted to have explosive gains over the next 30-90 days. In today's bull market, these stocks could climb even higher.
Ask Alexa!
Value stocks that also have growth are a rare combination. Who are the companies that are doing it in 2022? Zacks Value Strategist Tracey Ryniec serves as our guide.
New Strong Buy Stocks for February 25th
Now at home or on the go, hear the latest Zacks Rank and price of any ticker using Alexa!
Value Stocks vs. Ridiculously Overvalued Stocks
This diversified specialty materials producer has seen the Zacks Consensus Estimate for its current year earnings increasing 45.6% over the last 60 days.
Oil Rallies Amid Russia-Ukraine Crisis: ETFs to Bet On
Kevin Cook's Mind Over Money podcast welcomes back portfolio manager Nathan Miller of Emles Advisors to get our investing battle plans locked and loaded.